Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 28 results
Filters: Author is Tebas, Pablo  [Clear All Filters]
Found 28 results.

2007

McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
Dubé MP, Parker RA, Mulligan K, et al. "Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384." Clin. Infect. Dis.. 2007;45(1):120-6.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Currier JS, Kendall MA, W Henry K, et al. "Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults." AIDS. 2007;21(9):1137-45.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Mitsuyasu R, Gelman R, Cherng DWeng, et al. "The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328." Arch. Intern. Med.. 2007;167(6):597-605.